Of Interest

Five-year recurrence-free survival was 55.1% with nevus-associated acral melanoma (NAAM) vs. 42.3% with de novo acral melanoma (DNAM).

Vusolimogene oderparepvec plus nivolumab showed responses and a favorable safety profile in advanced melanoma post-anti–PD-1 therapy, per phase 2 IGNYTE trial data.

Data augmentation techniques like cropping and blurring allow AI models to overcome limited datasets, improving skin cancer detection rates.

A history of childhood cancer more than doubled the risk of melanoma and premature death in adults, a large retrospective review showed.